UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 16, 2006
Genelabs Technologies, Inc.
(Exact Name of Registrant as Specified in its Charter)
California 0-19222 94-3010150
- ------------------------------- ---------------------- ----------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
505 Penobscot Drive, Redwood City, California 94063
- -------------------------------------------------------- -------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 369-9500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule
or Standard; Transfer of Listing
On May 16, 2006, Genelabs Technologies, Inc. ("Genelabs" or the
"Company") received a staff determination letter from The Nasdaq Stock Market,
Inc. ("Nasdaq") stating that the Company's common stock is subject to delisting
from the Nasdaq Capital Market because the Company does not meet Nasdaq
Marketplace Rule 4310(c)(2)(B). The rule requires the Company to have a minimum
of $2,500,000 in shareholder's equity or $35,000,000 market value of listed
securities or $500,000 of net income from continuing operations for the most
recently completed fiscal year or two of the three most recently completed
fiscal years. Genelabs has the right to appeal the Nasdaq staff determination to
a Nasdaq Listings Qualification Panel ("Panel") and intends to timely request a
hearing. The request for a hearing will automatically stay the delisting of
Genelabs' common stock until the Panel reaches a decision.
A copy of the related press release is furnished as Exhibit 99.1
hereto.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits
Exhibit Number Description
- -------------- -----------
99.1 Press Release of Registrant, dated May 22, 2006,
entitled "Genelabs Plans to Appeal Staff Determination
Letter from Nasdaq Regarding its Listing on the Nasdaq
Capital Market"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Genelabs Technologies, Inc.
Date: May 22, 2006 By: /s/ Matthew M. Loar
---------------------------
Name: Matthew M. Loar
Title: Chief Financial Officer
EXHIBIT INDEX
Exhibit Number Description
- -------------- -----------
99.1 Press Release of Registrant, dated May 22, 2006.